16results about How to "Reduce lesions" patented technology

The invention discloses an endoscope system based on harmonic imaging and multiphoton fluorescence imaging. The endoscope system comprises a first femtosecond pulse laser, a second femtosecond pulse laser, a prism, an X-Y scanning galvanometer, a first long-wave-pass dichroscope, a coupling objective lens, an optical fiber bundle, an endoscope and an imaging device. The first femtosecond pulse laser and the second femtosecond pulse laser respectively emit near-infrared femtosecond pulse laser, the near-infrared femtosecond pulse laser enters the X-Y scanning galvanometer after being converged by the prism, then penetrates through the first long-wave-pass dichroscope, is coupled into the optical fiber bundle through the coupling objective lens, and finally is focused on a measured tissue through the endoscope. The first long-wave-pass dichroscope excites the detected tissue and the fluorescent substance thereof to generate second harmonic, third harmonic, two-photon fluorescence and three-photon fluorescence, and harmonic and fluorescence signals return along the same path and enter the imaging device after being reflected by the first long-wave-pass dichroscope, so that a second harmonic image, a third harmonic image, a two-photon fluorescence image and a three-photon fluorescence image of the detected tissue are obtained. Harmonic waves and multi-photon fluorescence imaging are combined, and pathological tissues in the cavity can be detected.

The invention relates to the technical field of biological medicine, in particular to radix puerariae and sesame coffee for improving non-alcoholic fatty liver and application of the radix puerariae and sesame coffee. The radix puerariae and sesame coffee comprises the following components in parts by weight: 0.5 part of a fructus cannabis polypeptide solution, 0.5 part of radix puerariae polypeptide solution and 9 parts of coffee. After continuous treatment for 7 weeks, according to liver appearance and liver histopathology observation, it is found that the radix puerariae and sesame coffee mixed liquid effectively reduces lipid deposition and liver fat, and the liver fat lesion is improved. Experimental results show that the radix puerariae and hemp coffee has a remarkable lipid-lowering effect, and can effectively reduce liver fat particles, reduce inflammatory injury, improve liver tissue pathological changes and relieve NAFLD mouse liver tissue injury.

Provided are Christensenellaceae, and a composition and a pharmaceutical use thereof. The Christensenellaceae can be used for treating or preventing liver function damage and related diseases, digestive tract mucosa damage and related diseases, diabetes, obesity, and related diseases. The Christensenellaceae can also be used in combination with hypoglycemic and lipid-lowering drugs, and has a synergistic effect on liver function damage and related diseases, diabetes, and obesity and related diseases.

The present invention provides a blood sugar lowering inulin fermentation product and its preparation and application, belonging to the field of microbial fermentation technology. The blood sugar lowering inulin fermentation product is obtained by fermenting inulin with a specific fermentation bacterium, Schleiferilactobacillus harbinensis JNDM, which has been deposited in the Guangdong Provincial Microbiological Culture Collection Center on December 11, 2023, with a deposit number of GDMCC No. 64143. The inulin fermentation product can significantly enhance the blood sugar lowering effect of inulin, reduce complications of hyperglycemia, improve anti-inflammatory function, and effectively relieve pancreatic and renal tissue lesions; it can regulate the homeostasis of intestinal flora, and significantly increase the diversity of intestinal microorganisms and the content of beneficial metabolites in the intestine. It can be used as a food, health product, medicine or functional beverage for preventing and treating type 2 diabetes and its complications or for lowering blood sugar.

The invention provides an anti-esophageal cancer medicine derived from fresh rabdosia rubescens and a preparation method of the anti-esophageal cancer medicine, and relates to the technical field of pharmacy of fresh traditional Chinese medicines. According to the invention, fresh rabdosia rubescens is taken as a basic medicinal material, an extraction process is improved and optimized, an extract containing Oridonin (Ori) and rosmarinic acid (RA) is obtained, and the esophageal cancer resisting effect of the fresh rabdosia rubescens extract is researched. Experimental results show that the treatment effect of Ori combined with RA administration on esophageal cancer model mice is remarkable, the effect is better than that of Ori or RA independent administration, and it is shown that oridonin and rosmarinic acid are combined for use, and the esophageal cancer resisting effect can be remarkably improved. The invention provides a novel medicine and a novel treatment thought for treating esophageal cancer.

The present invention discloses a strain of Enterococcus mundtii and its application. It belongs to the technical field of probiotics. A strain of Enterococcus mundtii is separated and identified by traditional identification methods and molecular biological methods, and its probiotic performance and in vivo safety evaluation are performed. At the same time, microbiology is combined with pathology, etc., and it is found that oral administration of the bacteria can reduce organ lesions in mice caused by Salmonella, and can produce antagonistic effects on Salmonella in mice. The present invention can not only expand the research on the genus Enterococcus, but also provide a reference basis for the future development of probiotic microecological preparations for promoting digestion and growth in animals, antagonizing pathogens, and regulating intestinal microecological environments.

The invention relates to a trichosanthes kirilowii maxim alkaloid extract and an extraction method and application thereof, and belongs to the technical field of trichosanthes kirilowii maxim extract preparation. The extraction method comprises the following steps: performing ultrasonic extraction on trichosanthes peel powder for multiple times by using a sulfuric acid solution, combining extracting solutions obtained by multiple times of extraction, performing primary concentration on the combined extracting solutions, then adjusting the pH value of the extracting solutions obtained by primary concentration to a target pH value, performing extraction for multiple times by using n-butyl alcohol, combining the extracting solutions obtained by multiple times of extraction, performing secondary concentration to obtain paste, and performing spray drying to obtain the trichosanthes peel extract. The trichosanthes kirilowii maxim alkaloid extract is obtained. The content of alkaloid in the trichosanthes kirilowii maxim alkaloid extract is 60-70%, and the trichosanthes kirilowii maxim alkaloid extract contains 20 kinds of alkaloid, has a good anti-atherosclerosis pharmacological action, and can remarkably improve liver lipid deposition, liver lipid metabolism disorder and abnormal blood lipid level of atherosclerosis mice.

The present invention belongs to the field of biotechnology, and specifically relates to the application of ISG15-(H4)2-IFN-λ3 recombinant protein in the preparation of drugs for preventing and treating PRRSV infection. The present invention selects (H4)2 connecting peptide to connect ISG15 and IFN-λ3 to prepare ISG15-(H4)2-IFN-λ3 recombinant protein, which can achieve stable and large-scale expression of IFN-λ3 protein, solves the technical problem that IFN-λ3 cannot be mass-produced using a prokaryotic expression system, and at the same time, the present invention verifies the anti-PRRSV activity of ISG15-(H4)2-IFN-λ3 recombinant protein in vivo, proving that the recombinantly expressed ISG15-(H4)2-IFN-λ3 recombinant protein has an inhibitory effect on inhibiting the replication of PRRSV in vivo, reduces the secretion of inflammatory factors in the lungs and improves the viremia caused by PRRSV infection.

The present application relates to the application of GBP4 gene silencing preparation in the preparation of drugs for preventing and treating atherosclerosis, and belongs to the technical field of biological medicine. In order to solve the technical problems that the existing atherosclerosis treatment target is single, cannot target regulate chronic inflammation of blood vessels, and is difficult to suppress disease progression from the root, the present application provides the application of GBP4 gene silencing preparation in the preparation of drugs for preventing and treating atherosclerosis, and the gene silencing preparation is a recombinant lentivirus vector carrying shRNA targeting GBP4. The present application first finds that GBP4 is a positive regulator of atherosclerosis, and the GBP4 gene silencing preparation can reduce the area of atherosclerotic plaque, delay the occurrence and development of atherosclerosis; increase the thickness of the fibrous cap of the plaque, enhance the stability of the plaque, and reduce the risk of plaque rupture; at the same time, reduce the systemic inflammation level, reduce the inflammatory response of the blood vessel wall, and have important clinical application value and broad market prospect.

The invention belongs to the technical field of transplanted vascular remodeling diagnosis and treatment, and discloses application of a reagent for inhibiting or detecting Fasn and a medicine for preventing and / or treating transplanted vascular remodeling. Experimental research discovers that a group of novel macrophages capable of self-synthesizing lipid exist in the transplantation blood vessel reconstruction process, and Fasn is remarkably activated, so that intracellular lipid accumulation is caused, and the macrophages are promoted to be converted into foam cells. In-vitro studies show that by inhibiting the activity of the Fasn enzyme or down-regulating the expression of the Fasn enzyme, the transformation of macrophages to foam cells can be obviously inhibited, and the synthesis of lipid in cells can be reduced. Based on the discovery, the nucleic acid medicine constructed by adopting the siRNA is used for treating and / or relieving transplanted vascular remodeling. In-vivo experiments further prove that the nucleic acid medicine can remarkably inhibit intimal hyperplasia of transplanted blood vessels and reduce the neointimal / medial membrane ratio, so that the therapeutic effect is achieved. The method has a good application prospect.

The present invention discloses an ophthalmic surgical device for sclera, comprising a manipulation module, a lifting control module and an arc-shaped shell, wherein the arc-shaped shell has a curvature and length adapted to the shape of the eyeball, and an open cavity is provided on one side of the arc-shaped shell for matching the sclera of the eyeball, wherein the lifting control module is installed in the open cavity, wherein the lifting control module is used to load and apply reinforcing materials and adhesive plasticizers to the sclera of the eyeball, wherein the manipulation module is connected to the lifting control module, and is used to manipulate the lifting control module to lift out of the open cavity to apply the reinforcing materials and adhesive plasticizers to the sclera of the eyeball, and manipulate the lifting control module to reset to the open cavity after the application is completed. The device of the present invention can attach the reinforcing materials to the surface of the posterior sclera through adhesive plasticizers in a minimally invasive, safe and accurately positioned manner, thereby achieving mechanical reinforcement of the posterior sclera, and enhancing constant pressure for the posterior pole or posterior scleral staphyloma.

The application relates to the technical field of animal infectious disease prevention and control, and particularly discloses application of tetrandrine in preparation of a medicine for preventing and treating pseudorabies of pigs. The application can significantly inhibit the replication efficiency of PRV on Vero cells and IPAM cells. When the concentration of the inhibitor is higher than 4 muM, the progeny virus titer and the virus gene transcription level of PRV are significantly reduced compared with those of a control group, and the pathological changes caused by cell infection are effectively relieved, which indicates that the tetrandrine can effectively inhibit the proliferation of PRV and has a potential application prospect.

The invention relates to the technical field of medicine application, and discloses mulberry leaf polysaccharide, a preparation method and application of the mulberry leaf polysaccharide in treatment of AFB1-induced mouse liver injury. The mulberry leaf polysaccharide can be independently used, and can also be combined with other traditional Chinese medicine extracts to prepare a pharmaceutical composition together. Experimental results show that the liver injury symptom of the mouse treated by the mulberry leaf polysaccharide is obviously improved, the liver index decline trend is relieved, and the liver lesion degree is obviously relieved. Therefore, the mulberry leaf polysaccharide disclosed by the invention can effectively treat liver injury caused by AFB1 and accompanied oxidative stress, and has a wide application prospect in the research field of mulberry leaf polysaccharide antioxidant preparations. The discovery not only provides powerful support for subsequent research and development of the polysaccharide, but also provides a new thought and direction for further optimization and innovation.

The present invention discloses a strain of Bacillus licheniformis and its application. It belongs to the technical field of probiotics. A strain of Bacillus licheniformis is separated and identified by traditional identification methods and molecular biological methods, and its probiotic performance and safety in animals are evaluated. At the same time, microbiology is combined with pathology, etc., and it is found that oral administration of the bacteria can reduce organ lesions in mice caused by Salmonella, and can produce antagonistic effects on Salmonella in mice. The present invention can not only expand the research on Bacillus, but also provide a reference basis for the future development of probiotic microecological preparations for promoting digestion and growth in animals, antagonizing pathogens, and regulating intestinal microecological environments.

The invention discloses application of magnolol and pharmaceutically acceptable salts thereof in inhibiting bone marrow-derived foam macrophage chronic inflammation after spinal cord injury. The invention provides application of magnolol in preparation of drugs for promoting discharge of macrophage lipid, drugs for promoting spinal cord injury repair, drugs for inhibiting lipid accumulation mediated secondary inflammation after spinal cord injury or neuroprotection drugs. The invention further provides a spinal cord injury repairing drug containing magnolol, a drug or reagent for promoting macrophage lipid excretion and a spinal cord inflammation inhibiting drug. According to the application disclosed by the invention, the magnolol is disclosed for the first time by regulating immune cell lipid excretion-inflammatory factor axis, so that the spinal nerve regeneration is obviously promoted, the nerve function is improved, the inflammatory reaction after lipid overload is relieved, and the spinal cord tissue is protected, and an innovative strategy is provided for spinal cord injury treatment. The magnolol synergistically intervenes the secondary neurodegenerative disease after spinal cord injury by improving lipid overload and immune dual pathways, and a brand new direction is provided for SCI treatment.